In the Claims:

Please amend the claims as follows:

Claim 1 (currently amended). ~~A viral~~ An adenoviral vector comprising an E2F responsive transcriptional nucleotide regulatory site that controls the expression of ~~a viral~~ an early adenoviral gene, and which adenoviral vector further comprises adenoviral packaging sequences that differ in the number of adenoviral packaging sequences, or position of said adenoviral packaging sequences when compared to Onyx 411.

Claims 2 – 29 - Canceled.

Claim 30 (currently amended). ~~A viral~~ An adenoviral vector as described in ~~claim 29~~ claim 1, wherein said adenoviral vector is of the R1 form.

Claim 31 (currently amended). ~~A viral~~ An adenoviral vector as described in ~~claim 29~~ claim 1, wherein said adenoviral vector is of the R2 form.

Claim 32 (currently amended). ~~A viral~~ An adenoviral vector as described in ~~claim 29~~ claim 1, wherein said adenoviral vector is of the R3 form.

Claim 33 (currently amended). A method for killing tumor cells, comprising contacting said tumor cells with ~~a viral~~ an adenoviral vector of ~~claim 28~~ claim 1.

Claims 34 – 35 - Canceled

Claim 36 (currently amended). A method for killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of ~~claim 35~~ claim 30.

-- Claim 37 (new). A method of killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 31.

Claim 38 (new). A method of killing tumor cells, comprising contacting said tumor cells with an adenoviral vector of claim 32.

Claim 39 (new). A method of making an adenoviral vector selected from the group consisting of R1, R2 or R3, comprising the steps of infecting cells with said adenoviral vector having the properties of Onyx 411, and allowing time for said Onyx 411 to replicate in said cells, then isolating from said cells said adenoviral vectors R1, R2, or R3.

Claim 40 (new). A method of making an adenoviral vector of claim 1, comprising the steps of infecting cells with a second adenoviral vector comprising two E2F responsive transcriptional nucleotide regulatory sites, which sites control the expression of two different early region adenoviral genes, and allowing time for said second adenoviral vector to replicate in said cells, then isolating from said cells said adenoviral vector of claim 1.

Claim 41 (new). A method as described in claim 40, wherein said adenoviral vector of claim 1 is selected from the group consisting of R1, R2, or R3.--